SCHEMBL17909778

SCHEMBL17909778

Cc1cc(C(N)=O)c(-c2ccc3nc(Cl)ccc3c2)c(C)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.38
▸ BACE1 P56817 4/20 0.37
▸ SYK P43405 1/20 0.36
▸ POLB P06746 1/20 0.35
▸ HPGD P15428 1/20 0.35
▸ NMT1 P30419 1/20 0.35
▸ FGFR4 P22455 1/20 0.35
▸ GRM2 Q14416 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CD38 P28907 1/20 0.34
▸ PIK3CD O00329 1/20 0.34
▸ ABL1 P00519 1/20 0.34
▸ EGFR P00533 1/20 0.34
▸ HCK P08631 1/20 0.34
▸ SRC P12931 1/20 0.34
▸ KDR P35968 1/20 0.34
▸ PIK3CA P42336 1/20 0.34
▸ PIK3CB P42338 1/20 0.34
▸ MTOR P42345 1/20 0.34
▸ PIK3CG P48736 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17909883 0.85 SYK (0.38) KDM4EBACE1SYKHPGDNMT1
SCHEMBL17909776 0.82 SRC (0.39) KDM4EBACE1SYKPOLBHPGD
SCHEMBL17909864 0.74 SYK (0.48) KDM4ESYKPOLBABL1KDR
SCHEMBL17909879 0.74 SRC (0.40) KDM4EBACE1SYKHPGDPIK3CD
SCHEMBL21292981 0.72 BACE1 (0.39) BACE1SYKPOLBHPGDNMT1
SCHEMBL21292982 0.72 HPGD (0.48) BACE1HPGDNMT1PIK3CDABL1
SCHEMBL20531652 0.71 HPGD (0.36) KDM4EBACE1SYKPOLBHPGD
SCHEMBL21292972 0.71 HPGD (0.36) KDM4EBACE1HPGDNMT1PIK3CD
SCHEMBL5470238 0.70 BACE1 (0.44) KDM4EBACE1HPGDNMT1CYP3A4
SCHEMBL18425042 0.70 KMO (0.39) BACE1HPGDPIK3CDABL1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200031799-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2020-01-30 — — US disclosed
US-10266515-B2 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. (BB) 2019-04-23 — — US disclosed
US-10259803-B2 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. (BB) 2019-04-16 — — US disclosed
US-20180170906-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2018-06-21 — — US disclosed
US-20170260163-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2017-09-14 — — US disclosed
US-9611252-B2 Therapeutic inhibitory compounds LIFESCI PHARMACEUTICALS, INC. (BB) 2017-04-04 — — US disclosed
US-20160200704-A1 THERAPEUTIC INHIBITORY COMPOUNDS ATTUNE PHARMACEUTICALS, INC. 2016-07-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200031799-A1 THERAPEUTIC INHIBITORY COMPOUNDS KLKB1, SERPINB1, SERPINE1 KDM4E 798/4885BACE1 1688/4885SYK 1810/4885
US-20180170906-A1 THERAPEUTIC INHIBITORY COMPOUNDS KLKB1, SERPINB1, SERPINE1 KDM4E 798/4885BACE1 1688/4885SYK 1810/4885
US-20170260163-A1 THERAPEUTIC INHIBITORY COMPOUNDS KLKB1, SERPINB1, SERPINE1 KDM4E 798/4885BACE1 1688/4885SYK 1810/4885
US-20160200704-A1 THERAPEUTIC INHIBITORY COMPOUNDS KLKB1, SERPINB1, SERPINE1 KDM4E 798/4885BACE1 1688/4885SYK 1810/4885
US-10266515-B2 Therapeutic inhibitory compounds KLKB1, SERPINB1, SERPINE1 KDM4E 798/4885BACE1 1688/4885SYK 1810/4885
US-10259803-B2 Therapeutic inhibitory compounds KLKB1, SERPINB1, SERPINE1 KDM4E 798/4885BACE1 1688/4885SYK 1810/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback